|Roy Baynes, MB.BCh., M.Med., PhD, FCP, FACP|
Roy Baynes has served as a member of our board of directors since August 2018. Dr. Baynes is Chief Medical Officer at Merck, and Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories. Dr. Baynes was previously Senior Vice President of Oncology, Inflammation, and Respiratory Therapeutics at Gilead Sciences, and also served as Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology at Amgen. Dr. Baynes has had a long and distinguished career in the hematology, oncology, and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching, and administration. He is a member of the American Society of Hematology, American Society of Clinical Oncology, and American Association for Cancer Research, and has authored about 150 publications. Before joining industry in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Baynes graduated as a medical doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand in Johannesburg, South Africa.
|Roelof F. Botha|
Roelof F. Botha has served as a member of our board of directors since 2007. Mr. Botha has been with
Sequoia Capital, a venture capital firm, since 2003, and has been a Managing Member of Sequoia Capital
Operations, LLC since 2007. From 2000 to 2003, Mr. Botha served in a number of roles at PayPal, Inc., most recently as the Chief Financial Officer. From 1996 to 1998, Mr. Botha served as a management consultant for McKinsey & Company, a management consulting firm. Mr. Botha currently serves on the board of directors of Xoom Corporation, a provider of global money transfer services, and a number of privately-held companies.
Steve Chapman has served as the Company’s Chief Executive Officer, and as a director on its board of directors, since January 2019. Previously, Mr. Chapman served as the company’s Chief Operating Officer from August 2017 to January 2019, and Chief Commercial Officer from March 2017 to August 2017. Mr. Chapman began working at Natera, Inc. in December 2010 and held positions including the Vice President of Sales and Vice President, Commercial Operations. Mr. Chapman worked previously at Genzyme Genetics Corp., a biotechnology company, from 2003 to 2010. Mr. Chapman holds a Bachelor of Science in Microbiology, Immunology and Molecular Genetics from University of California, Los Angeles.
Todd Cozzens has served as a member of our board of directors since 2011. Mr. Cozzens has been with
Sequoia Capital, a venture capital firm, since 2012. From 2010 to 2012, Mr. Cozzens served as Chief
Executive Officer of Optum Accountable Care Solutions, a business unit of Optum/United Healthcare Group. From 2000 to 2010,
Mr. Cozzens served as Chief Executive Officer of Picis Inc., a provider of electronic medical record software to hospitals, until its acquisition by the UnitedHealth Group in 2010. Mr. Cozzens currently serves on the boards of directors of a number of privately held companies.
|Edward C. Driscoll, Jr., Ph.D.|
Edward C. Driscoll, Jr., Ph.D. has served as a member of our board of directors since 2007. Dr. Driscoll has been with Claremont Creek Ventures, a venture capital firm, since 2006. From January 2007 to
February 2010, Dr. Driscoll served as a Venture Partner at Claremont Creek Ventures. From February
2010 to July 2012, Dr. Driscoll served as a Technology Partner. Since July 2012, Dr. Driscoll has served as a Director at Claremont Creek Ventures. In addition, Dr. Driscoll was an angel investor with Health Tech
Capital, Silicom Ventures and Sand Hill Angels from June 2005 to December 2013. From December 1995 to April 2005, Dr. Driscoll was founder, President and Chief Executive Officer of Be Here Corporation, an internet, broadcast and videoconferencing technology company. From June 1993 to June 1995, Dr. Driscoll served as Chief Executive Officer of Focus Surgery, Inc., a non-invasive surgical equipment company that was spun off from Diasonics, Inc., a digital imaging and medical device company. From December 1987 to June 1993, Dr. Driscoll held various roles at Diasonics, including President of the Therapeutic Products Division and Chief Technology Officer. From December 1993 to December 2013, Dr. Driscoll held elected roles for the town of Portola Valley. Dr. Driscoll currently serves on the boards of directors of a number of privately held companies. Dr. Driscoll holds a Bachelor of Arts degree in Architecture from the University of Pennsylvania, a Master of Architecture and Landscape Architecture from Harvard University and a Ph.D. in Applied Earth Sciences from Stanford University.
|James I. Healy, M.D., Ph.D.|
James I. Healy, M.D., Ph.D. has served as a member of our board of directors since November 2014.
Dr. Healy has been a General Partner at Sofinnova Ventures, a venture capital firm, since 2000. Prior to
June 2000, Dr. Healy held various positions at Sanderling Ventures, a venture capital firm, Bayer
Healthcare Pharmaceuticals (as successor to Miles Laboratories), a research-based pharmaceutical company and ISTA Pharmaceuticals, Inc., a company specializing in ophthalmic pharmaceutical products.
Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, a clinical-stage biopharmaceutical company, Amarin Corporation plc, a commercial-stage biopharmaceutical company,
Auris Medical Holding AG, a specialty pharmaceutical company focused on tinnitus, Coherus BioSciences, Inc., a biologics platform company, and several private companies. Previously, Dr. Healy served as a board member of Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammation and autoimmune diseases, from 2006 to 2014; Durata Therapeutics, Inc., a pharmaceutical company focused on infectious and acute diseases, from 2009 to 2013; InterMune, Inc., a biotechnology company focused on orphan fibrotic pulmonary disease, from 1999 to 2014; KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of monoclonal antibody therapeutics, from 2001 to 2014; Hyperion Therapeutics, Inc., a commercial-stage orphan disease company, from 2007 to 2015 and several private companies. Dr. Healy holds an M.D. and Ph.D. in Immunology from Stanford University School of Medicine and performed neuroscience research at the University of Virginia School of Medicine. Dr. Healy holds a Bachelors of Arts in Molecular Biology and Scandinavian Studies from the University of California at Berkeley.
Gail Marcus has served as a member of our board of directors since March 2017. Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International, a consulting company, since 2015, and as an Assistant Professor & Director of the Global Healthcare Management and Biomedical Informatics programs at the Massachusetts College of Pharmacy and Health Sciences since 2016. From 2012 to 2015, Ms. Marcus served as Chief Executive Officer and President of Calloway Laboratories, a provider of clinical toxicology laboratory services. Prior to that, Ms. Marcus held a variety of leadership roles with diagnostics, pharmacy benefit management and managed care companies. Ms. Marcus currently serves on the boards of directors of a private company and a non-profit organization, and sits on the Centers for Medicare & Medicaid Services Advisory Panel on Clinical Diagnostic Laboratory Tests. Our board of directors believes that Ms. Marcus is qualified to serve as a director based on her financial and managerial experience and service on other boards of directors. Ms. Marcus holds a Bachelor of Art degree in Spanish and Mathematics from Wesleyan University, an M.S.E. in Computer and Information Sciences from the University of Pennsylvania Moore School of Engineering, an M.B.A. from the Wharton School of the University of Pennsylvania, and is pursuing a Doctorate of Health Administration from the Medical University of South Carolina.
|Matthew Rabinowitz, Ph.D.|
Executive Chairman of the Board
Matthew Rabinowitz, Ph.D. is a co-founder of our company and has served as a member of our board of directors and as our Chief Executive Officer since 2005 and as Chairman of our board of directors since May 2015. Prior to co-founding our company, Dr. Rabinowitz served from 2000 to 2003 as Chief Executive Officer and from 2003 to 2007 as Chief Technology Officer of Rosum Corporation, a location-services technology company. From 1998 to 2000, Dr. Rabinowitz served as co-founder and Chief Scientist of Panop.com Inc., an online merchandizing company. Dr. Rabinowitz served as a consulting professor at Stanford University from 2004 to 2012. He has multiple publications in signal processing, machine learning, bio-informatics, and high-throughput genetic testing. He received the Scott Helt Memorial Award from the IEEE and received Technology Pioneer Awards from the World Economic Forum for founding Rosum and Natera. He currently serves on the advisory boards or boards of directors of multiple privately held companies. Dr. Rabinowitz holds a Bachelor of Science degree in Physics from Stanford University, a Master of Science in Electrical Engineering from Stanford University and a Ph.D. in Electrical Engineering from Stanford University.
Herm Rosenman served as our Chief Financial Officer from February 2014 to January 2017, and has served as a member of our board of directors since February 2017. Prior to joining our company, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial stage diagnostics company, since 2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to 2014; ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009; Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee, from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
Jonathan Sheena is a co-founder of our company and has served as a member of our board of directors and as our Chief Technology Officer since 2007. In 1999, Mr. Sheena co-founded PhoneSpots, Inc. (formerly PocketThis, Inc.), a mobile technology company serving mobile carriers worldwide. From June
1999 to December 2007, Mr. Sheena held various roles at PhoneSpots, including Vice President of Product Management and Chief Technology Officer. Mr. Sheena holds a Bachelor of Science in Electrical
Engineering and Computer Science from the Massachusetts Institute of Technology and a Master of
Engineering in Electrical Engineering and Computer Science from the Massachusetts Institute of